SRR8942940
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.550
- G2M_CHECKPOINT+0.430
- DNA_REPAIR+0.330
- MITOTIC_SPINDLE+0.240
- SPERMATOGENESIS+0.240
- MYC_TARGETS_V1+0.220
- PROTEIN_SECRETION+0.120
- OXIDATIVE_PHOSPHORYLATION+0.100
- PI3K_AKT_MTOR_SIGNALING+0.080
- ALLOGRAFT_REJECTION+0.050
Top 10 suppressed
- ANGIOGENESIS-0.460
- TNFA_SIGNALING_VIA_NFKB-0.440
- NOTCH_SIGNALING-0.420
- HYPOXIA-0.400
- TGF_BETA_SIGNALING-0.400
- P53_PATHWAY-0.350
- ESTROGEN_RESPONSE_EARLY-0.340
- APICAL_SURFACE-0.320
- WNT_BETA_CATENIN_SIGNALING-0.310
- XENOBIOTIC_METABOLISM-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8942939 | — | — | 0.877 |
| 2 | SRR8518197 | — | E | 0.861 |
| 3 | MDT-AP-0392 | Med | Medulloblastoma | 0.861 |
| 4 | TCGA-43-7658-01A-11R-2125-07 | — | cohortMD1 | 0.856 |
| 5 | R160 | — | — | 0.854 |
| 6 | SRR12202426 | — | — | 0.850 |
| 7 | SRR1797285 | — | cohortSC | 0.849 |
| 8 | SRR13780255 | — | cohortSC | 0.848 |
| 9 | BS_TYAYZ9ZW | Med | Medulloblastoma | 0.846 |
| 10 | SRR12202422 | — | — | 0.841 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.550 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.430 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.330 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.240 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.220 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.120 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.100 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.080 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.050 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |